{"article_title": "FDA Approval Of Key Instruments Could Boost Sales Of Intuitive Surgical's da Vinci Xi", "article_keywords": ["fda", "xi", "vinci", "intuitive", "instruments", "sales", "da", "surgicals", "key", "boost"], "article_url": "http://www.forbes.com/sites/greatspeculations/2014/08/27/fda-approval-of-key-instruments-could-boost-sales-of-intuitive-surgicals-da-vinci-xi/", "article_text": "", "article_metadata": {"prerender-status-code": "{{meta.code}}", "author": "Great Speculations", "og": {"site_name": "Forbes", "description": "The recent approvals are certainly good news for the company considering that it has struggled with declining sales and safety issues with its da Vinci surgical robotic systems in the last year. If the da Vinci Xi can offer more advantages and cost effectiveness to surgeons than regular open procedures or, better still, laparoscopic procedures, it could aid the company in earning back customer confidence and reversing its declining sales.", "title": "FDA Approval Of Key Instruments Could Boost Sales Of Intuitive Surgical's da Vinci Xi", "url": "http://www.forbes.com/sites/greatspeculations/2014/08/27/fda-approval-of-key-instruments-could-boost-sales-of-intuitive-surgicals-da-vinci-xi/", "image": "http://i.forbesimg.com/media/assets/forbes_1200x1200.jpg", "updated_time": "2014-08-27T08:45:58-04:00", "type": "article"}, "twitter": {"image": "http://i.forbesimg.com/media/assets/forbes_1200x1200.jpg", "description": "The recent approvals are certainly good news for the company considering that it has struggled with declining sales and safety issues with its da Vinci surgical robotic systems in the last year. If the da Vinci Xi can offer more advantages and cost effectiveness to surgeons than regular open procedures or, better still, laparoscopic procedures, it could aid the company in earning back customer confidence and reversing its declining sales.", "site": "@forbes", "card": "summary_large_image", "title": "FDA Approval Of Key Instruments Could Boost Sales Of Intuitive Surgical's da Vinci Xi"}, "apple-itunes-app": "app-id=588647136", "fb": {"app_id": 123694841080850}, "keywords": "Investing,Markets,Stocks", "article": {"publisher": "https://www.facebook.com/forbes", "section_url": "http://www.forbes.com/investing", "section": "Investing", "modified": "2014-08-27", "published": "2014-08-27", "id": "blogAndPostId/blog/post/25-132990"}, "news_keywords": "Investing,Markets,Stocks", "viewport": "width=device-width,initial-scale=1,maximum-scale=1,user-scalable=no", "description": "The recent approvals are certainly good news for the company considering that it has struggled with declining sales and safety issues with its da Vinci surgical robotic systems in the last year. If the da Vinci Xi can offer more advantages and cost effectiveness to surgeons than regular open procedures or, better still, laparoscopic procedures, it could aid the company in earning back customer confidence and reversing its declining sales."}, "_id": "\"57477af36914bd0286fccef1\"", "article_summary": ""}